CHICAGO — Consumers taking glucagon-like peptide-1 (GLP-1) medicines specifically for weight loss make fewer food and beverage purchases during their first three months of use, with spending returning closer to benchmark levels by the end of year one. That’s according to “The Ripple Effect of GLP-1s, Today and In the Future,” a new report from Circana that explores GLP-1s’ impact on consumer spending.
The findings provide CPG companies with actionable insights to develop personalized products and services that support consumers’ sustainable lifestyle changes and long-term weight management success.